Researcher Next
Create account
← Back to directory

Libor Havel

Researcher Next ID · RN-009596

Researcher · Medicine

Charles University

, Czechia

Sign in to saveSign in to claim
Not currently recruitingFunding unknown
Works count
237
Citation count
30,324
H-index
38
i10-index
52

Research interests

Medicine
Lung Cancer Research Studies
Neuroendocrine Tumor Research Advances
Peptidase Inhibition and Analysis
Lung Cancer Treatments and Mutations
Lung Cancer Diagnosis and Treatment

Publications

  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    The Lancet · 2019 · 10.1016/s0140-6736(18)32409-7

  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    The Lancet · 2019 · 10.1016/s0140-6736(19)32222-6

  • First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

    New England Journal of Medicine · 2018 · 10.1056/nejmoa1809064

  • First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    New England Journal of Medicine · 2017 · 10.1056/nejmoa1613493

  • Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

    New England Journal of Medicine · 2015 · 10.1056/nejmoa1504627

Current projects

    No projects listed.